Ukoniq (umbralisib) — Medica
mucosa-associated lymphoid tissue (MALT) lymphoma
Initial criteria
- age ≥ 18 years
- patient has gastric MALT OR non-gastric/non-cutaneous MALT
- patient has received at least one prior anti-CD20-based regimen
Approval duration
3 years